Gaia Healthcare showcased its Combiplax at the Heart to Heart Care 2024 event in Dubai, a platform for raising awareness about cardiovascular health and overall well-being. The product is the first dual anti-platelet therapy in the GCC region, IT combines Clopidogrel and Acetylsalicylic Acid (aspirin), and offers dual-action benefits, making it an essential treatment option for patients at high risk of heart attacks or strokes.
Combiplax is designed to inhibit blood clot formation in patients with cardiovascular disease, providing a preventive solution against life-threatening events. Its synergy between Clopidogrel, a platelet aggregation inhibitor, and Acetylsalicylic Acid reduces the tendency of blood to clot, providing comprehensive protection to those most vulnerable to heart-related conditions. This dual-action approach is particularly valuable for individuals who have experienced heart attacks, strokes, or other cardiovascular complications.
The event, held at Zaabeel Park, attracted thousands of health-conscious individuals to learn more about the latest in heart health solutions. Gaia Healthcare’s booth provided visitors with in-depth insights into Combiplax’s benefits, mechanism of action, and critical role in cardiovascular health. Attendees had the opportunity to engage directly with Gaia’s healthcare professionals, asking questions and learning about preventive measures that align with their lifestyle needs.
Gaia Healthcare’s participation in Heart to Heart Care 2024 reflects its commitment to improving community health through innovative solutions. As cardiovascular health remains a leading global health concern, Gaia Healthcare continues to invest in community engagement to bring high-quality, effective healthcare solutions like Combiplax to the forefront.
